All Pharma News
REGENXBIO Announces Lancet Publication of Phase I/IIa Study of ABBV-RGX-314

REGENXBIO Announces Lancet Publication of Phase I/IIa Study of ABBV-RGX-314
PR NEWSWIRE
28 Mar 2024
Share Share
REGENXBIO to Participate in Cantor Fitzgerald`s Virtual DMD and Other Dystrophy Days

REGENXBIO to Participate in Cantor Fitzgerald`s Virtual DMD and Other Dystrophy Days
PRESS RELEASE
27 Mar 2024
Share Share
REGENXBIO to Participate in Upcoming Investor Conferences

REGENXBIO to Participate in Upcoming Investor Conferences
PRESS RELEASE
11 Mar 2024
Share Share
REGENXBIO Announces Pricing of Upsized Public Offering of Common Stock

REGENXBIO Announces Pricing of Upsized Public Offering of Common Stock
PRESS RELEASE
06 Mar 2024
Share Share
REGENXBIO Announces Proposed Public Offering of Common Stock

REGENXBIO Announces Proposed Public Offering of Common Stock
PR NEWSWIRE
06 Mar 2024
Share Share
Regenxbio Announces New Initial Efficacy Data From Affinity Duchenne® Trial

Regenxbio Announces New Initial Efficacy Data From Affinity Duchenne® Trial
PR NEWSWIRE
05 Mar 2024
Share Share
REGENXBIO’s Research and Development Facility, Maryland, US

REGENXBIO’s Research and Development Facility, Maryland, US
PHARMACEUTICAL TECHNOLOGY
01 Mar 2024
Share Share
REGENXBIO to Host Webcast to Discuss Data from Ph I/II AFFINITY DUCHENNE® Trial

REGENXBIO to Host Webcast to Discuss Data from Ph I/II AFFINITY DUCHENNE® Trial
PR NEWSWIRE
29 Feb 2024
Share Share
REGENXBIO to Host Event to Discuss Data from Phase I/II AFFINITY DUCHENNE Trial

REGENXBIO to Host Event to Discuss Data from Phase I/II AFFINITY DUCHENNE Trial
PRESS RELEASE
29 Feb 2024
Share Share
REGENXBIO Reports Fourth Quarter and Full Year 2023 Financial Results

REGENXBIO Reports Fourth Quarter and Full Year 2023 Financial Results
PR NEWSWIRE
27 Feb 2024
Share Share